Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Yuri Machiba"'
Autor:
Katsuhito Mori, Tsutomu Inoue, Yuri Machiba, Hideki Uedono, Shinya Nakatani, Masahiro Ishikawa, Satsuki Taniuchi, Yutaka Katayama, Akira Yamamoto, Naoki Kobayashi, Eito Kozawa, Taro Shimono, Yukio Miki, Hirokazu Okada, Masanori Emoto
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundRecent clinical studies suggest protective effects of SGLT2 inhibitors on kidney disease outcome. Chronic hypoxia has a critical role in kidney disease development, thus we speculated that canagliflozin, an SGLT2 inhibitor, can improve kidn
Externí odkaz:
https://doaj.org/article/4e751c838da845bab3424f6068999ade
Autor:
Shinya Nakatani, Kozo Nishide, Senji Okuno, Eiji Ishimura, Daijiro Kabata, Fumiyuki Morioka, Yuri Machiba, Hideki Uedono, Akihiro Tsuda, Shigeichi Shoji, Masaaki Inaba, Katsuhito Mori, Tomoyuki Yamakawa, Masanori Emoto
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract A massively enlarged kidney can impact quality of life of autosomal dominant polycystic kidney disease (ADPKD) patients. A recent in vitro study demonstrated that an allosteric modulator of the calcium sensing receptor decreases adenosine-3
Externí odkaz:
https://doaj.org/article/4d7d233e64e54f819c340bec880d0e73
Autor:
Akihiro Tsuda, Eiji Ishimura, Yuri Machiba, Hideki Uedono, Shinya Nakatani, Katsuhito Mori, Junji Uchida, Masanori Emoto
Publikováno v:
Kidney & Blood Pressure Research, Pp 1-13 (2020)
Background: Cr is secreted by the proximal tubules and thus Cr clearance (Ccr) can overestimate inulin clearance (Cin). However, in some cases, Ccr can even underestimate Cin. This suggests that Cr could be reabsorbed in the tubuli. We examined the c
Externí odkaz:
https://doaj.org/article/3bbf2d18e17a48cc9e52b243d7877bf4
Autor:
Shinya Nakatani, Eiji Ishimura, Yuri Machiba, Kenta Fujimoto, Hideki Uedono, Akihiro Tsuda, Katsuhito Mori, Masanori Emoto, Masaaki Inaba
Publikováno v:
Case Reports in Nephrology and Dialysis, Vol 10, Iss 1, Pp 9-17 (2020)
Tolvaptan, a vasopressin V2 receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD). Recently, a retrospective study showed that the effect of tolvaptan on kidney function could be su
Externí odkaz:
https://doaj.org/article/4dfdc5727e88458297af2366afb44e13
Autor:
Katsuhito Mori, Tsutomu Inoue, Yuri Machiba, Hideki Uedono, Shinya Nakatani, Masahiro Ishikawa, Satsuki Taniuchi, Yutaka Katayama, Akira Yamamoto, Naoki Kobayashi, Eito Kozawa, Taro Shimono, Yukio Miki, Hirokazu Okada, Masanori Emoto
Publikováno v:
Frontiers in Endocrinology; 2024, p1-9, 9p
Autor:
Yuri Machiba, Katsuhito Mori, Tetsuo Shoji, Yuki Nagata, Hideki Uedono, Shinya Nakatani, Akinobu Ochi, Akihiro Tsuda, Tomoaki Morioka, Hisako Yoshida, Yoshihiro Tsujimoto, Masanori Emoto
Publikováno v:
Journal of Renal Nutrition. 32:751-757
Infection is related to a higher rate of hospitalization and subsequent death in patients undergoing hemodialysis. Limited data are available about factors associated with death after hospitalization for infection. Nutritional disorder also known as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f459968fcb47949b5636454667471a90
https://doi.org/10.1053/j.jrn.2022.01.008
https://doi.org/10.1053/j.jrn.2022.01.008
Autor:
Fumiyuki Morioka, Shinya Nakatani, Kozo Nishide, Yuri Machiba, Hideki Uedono, Akihiro Tsuda, Eiji Ishimura, Katsuhito Mori, Masanori Emoto
Publikováno v:
Clinical and Experimental Nephrology. 26:955-962
Minimal change nephrotic syndrome (MCNS) is a common type of nephrotic syndrome in adults, though evidence regarding its clinical and histopathological features related to time to complete remission (CR) is limited.This was a retrospective study of b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b6855ba687f05897e7105b7a40159dd
https://doi.org/10.1007/s10157-022-02235-8
https://doi.org/10.1007/s10157-022-02235-8
Autor:
Hideki Uedono, Akihiro Tsuda, Noriko Ueno, Yuka Natsuki, Rino Nakaya, Kozo Nishide, Yuri Machiba, Kenta Fujimoto, Shinya Nakatani, Katsuhito Mori, Masanori Emoto
Publikováno v:
Internal medicine (Tokyo, Japan). 61(23)
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease. Lupus nephritis (LN) is a major risk factor for mortality in SLE, and glomerular "full-house" immunofluorescence staining is a well-known characteristic of LN. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09684142f5386044e6c21dd7823c8cef
https://pubmed.ncbi.nlm.nih.gov/35527024
https://pubmed.ncbi.nlm.nih.gov/35527024
Autor:
Masaaki Inaba, Fumiyuki Morioka, Eiji Ishimura, Akihiro Tsuda, Hideki Uedono, Yuri Machiba, Katsuhito Mori, Masanori Emoto, Shinya Nakatani, Kozo Nishide
Publikováno v:
Clinical and Experimental Nephrology. 25:261-269
Acute kidney injury (AKI) is a common complication of minimal change nephrotic syndrome (MCNS), particularly in adults. To predict development of AKI, as defined by the Kidney Disease Improving Global Outcomes classification, we investigated clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62beb73be912dbc32067516c4f673261
https://doi.org/10.1007/s10157-020-01992-8
https://doi.org/10.1007/s10157-020-01992-8
Autor:
Eiji Ishimura, Hideki Uedono, Shinya Nakatani, Masanori Emoto, Katsuhito Mori, Yuri Machiba, Kenta Fujimoto, Masaaki Inaba, Akihiro Tsuda
Publikováno v:
Case Reports in Nephrology and Dialysis
Case Reports in Nephrology and Dialysis, Vol 10, Iss 1, Pp 9-17 (2020)
Case Reports in Nephrology and Dialysis, Vol 10, Iss 1, Pp 9-17 (2020)
Tolvaptan, a vasopressin V2 receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD). Recently, a retrospective study showed that the effect of tolvaptan on kidney function could be su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f59fd051846d377eafe1a7cd6e2a7208
http://europepmc.org/articles/PMC7098338
http://europepmc.org/articles/PMC7098338